The immunomodulatory role of all-trans retinoic acid in tumor microenvironment

Bi, Guoshu; Liang, Jiaqi; Bian, Yunyi; Shan, Guangyao; Besskaya, Valeria; Wang, Qun; Zhan, Cheng

doi:10.1007/s10238-022-00860-x

Cited by 6 publications

(2 citation statements)

References 164 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a study by Ma ZL et al ( Ma et al, 2022 ) found that ATRA antagonized the function of PD-L1 antibody in GC, and ATRA induced the expression of PD-L1 in GC, which made GC cells highly resistant to killing by activated T cells. ATRA can greatly weaken the immunosuppressive effects of infiltrating MDSC and also activate the antitumor effects of CD8 + T cells, and the combination of ATRA with immune checkpoint inhibitors, tumor vaccines, and chemotherapy has been widely studied in a variety of tumors ( Bi et al, 2023 ). ATRA not only plays a crucial role in inducing intestinal tropism of lymphocytes and regulating T helper cell differentiation, but is also an important regulator of innate immune cells such as tolerogenic dendritic cells (DCs) and innate lymphoid cells (ILCs) ( Czarnewski et al, 2017 ).…”

Section: Roles Of Atra In the Treatment Of Diseasesmentioning

confidence: 99%

All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia

Chen,

Tong,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

All-trans retinoic acid (ATRA) plays a role in tissue development, neural function, reproduction, vision, cell growth and differentiation, tumor immunity, and apoptosis. ATRA can act by inducing autophagic signaling, angiogenesis, cell differentiation, apoptosis, and immune function. In the blood system ATRA was first used with great success in acute promyelocytic leukemia (APL), where ATRA differentiated leukemia cells into mature granulocytes. ATRA can play a role not only in APL, but may also play a role in other hematologic diseases such as immune thrombocytopenia (ITP), myelodysplastic syndromes (MDS), non-APL acute myeloid leukemia (AML), aplastic anemia (AA), multiple myeloma (MM), etc., especially by regulating mesenchymal stem cells and regulatory T cells for the treatment of ITP. ATRA can also increase the expression of CD38 expressed by tumor cells, thus improving the efficacy of daratumumab and CD38-CART. In this review, we focus on the mechanism of action of ATRA, its role in various hematologic diseases, drug combinations, and ongoing clinical trials.

show abstract

Section: Roles Of Atra In the Treatment Of Diseasesmentioning

confidence: 99%

All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia

Chen,

Tong,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Lastly, another credible strategy is to reduce the production of MDSC populations. All-trans-retinoic acid (ATRA) binding to the retinoid receptor could induce the immature myeloid cell (IMC) population to differentiate into macrophages and dendritic cells, neutralize high ROS production and increase glutathione synthase ( Liu et al, 2021b ; Bi et al, 2022 ). ATRA administration or combined with other immunotherapies increased the number of T cells, enhanced dendritic cell functions, and downregulated the ROS generation in MDSCs, resulting in improving anti-tumor immunity ( Li et al, 2014 ; Bauer et al, 2018 ; Tobin et al, 2018 ).…”

Section: Effector Phasementioning

confidence: 99%

The soldiers needed to be awakened: Tumor-infiltrating immune cells

Wang

Zhuling³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

In the tumor microenvironment, tumor-infiltrating immune cells (TIICs) are a key component. Different types of TIICs play distinct roles. CD8+ T cells and natural killer (NK) cells could secrete soluble factors to hinder tumor cell growth, whereas regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) release inhibitory factors to promote tumor growth and progression. In the meantime, a growing body of evidence illustrates that the balance between pro- and anti-tumor responses of TIICs is associated with the prognosis in the tumor microenvironment. Therefore, in order to boost anti-tumor response and improve the clinical outcome of tumor patients, a variety of anti-tumor strategies for targeting TIICs based on their respective functions have been developed and obtained good treatment benefits, including mainly immune checkpoint blockade (ICB), adoptive cell therapies (ACT), chimeric antigen receptor (CAR) T cells, and various monoclonal antibodies. In recent years, the tumor-specific features of immune cells are further investigated by various methods, such as using single-cell RNA sequencing (scRNA-seq), and the results indicate that these cells have diverse phenotypes in different types of tumors and emerge inconsistent therapeutic responses. Hence, we concluded the recent advances in tumor-infiltrating immune cells, including functions, prognostic values, and various immunotherapy strategies for each immune cell in different tumors.

show abstract